European Journal of Clinical Pharmacology

, Volume 69, Issue 1, pp 11–20 | Cite as

Pharmacokinetic–pharmacodynamic model of fimasartan applied to predict the influence of a high fat diet on its blood pressure-lowering effect in healthy subjects

  • Jongtae Lee
  • Seunghoon Han
  • Sangil Jeon
  • Taegon Hong
  • Dong-Seok Yim



Fimasartan is a non-peptide angiotensin II receptor antagonist which selectively blocks the AT1 receptor. The aim of our study was to perform a population pharmacokinetic–pharmacodynamic (PK–PD) analysis of fimasartan to evaluate the effect of food on the mechanistic PK–PD relationship.


This was a food–drug interaction single-center study involving 24 healthy subjects that was designed as a randomized, open-label, single-dosing, two-way crossover trial. Extensive PK data was obtained on blood samples collected at 0, 0.5, 1, 2, 2.5, 3, 4, 6, 8, 12, and 24 h post-dosing and five systolic/diastolic blood pressure (BP) measurements made at 0, 4, 8, 12 and 24 h post-dosing and used to construct a mixed effect model (NONMEM, ver. 6.2).


A two-compartment linear PK model with zero-order (fasted) or Weibull (fed with high-fat diet) absorption best described the PK of fimasartan. Relative bioavailability decreased by 37 % when the subjects were given a high-fat diet.


The turnover PK–PD model combined with pre-defined cosine function for circadian rhythm described the BP changes measured within 24 h after dosing better than the effect compartment or transduction models. To predict the influence of a high-fat diet on the blood pressure-lowering effect of fimasartan in healthy subjects, we simulated changes in BP when fimasartan was given daily for 30 days. The overlapping pattern of simulated BP curves in the fasted versus fed group demonstrated that a high-fat diet would not cause a clinically significant reduction in the BP-lowering effect of fimasartan, despite a significant reduction in bioavailability.


Fimasartan NONMEM Food effect PK–PD modeling Blood pressure 



This study was sponsored by Boryung Pharmaceutical Co, Ltd, the manufacturer of fimasartan.


  1. 1.
    Csajka C, Buclin T, Fattinger K, Brunner HR, Biollaz J (2002) Population pharmacokinetic-pharmacodynamic modeling of angiotensin receptor blockade in healthy volunteers. Clin Pharmacokinet 41:137–152PubMedCrossRefGoogle Scholar
  2. 2.
    Tanigawara Y, Yoshihara K, Kuramoto K, Arakawa K (2009) Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis. Drug Metab Pharmacokinet 24:376–388PubMedCrossRefGoogle Scholar
  3. 3.
    Korea National Institute of Toxicological Research (2005) Guideline on food-effect bioavailability and fed bioequivalence studies. Accessed 22 Feb 2012
  4. 4.
    Yi S, Kim TE, Yoon SH et al (2011) Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. Cardiovasc Pharmacol 57(6):682–689CrossRefGoogle Scholar
  5. 5.
    Zhou H, Kalilieh S, Lau H et al (1999) Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). J Clin Pharmacol 39:911–919PubMedCrossRefGoogle Scholar
  6. 6.
    Hempel G, Karlsson MO, de Alwis DP, Toublanc N, McNay J, Schaefer HG (1998) Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements. Clin Pharmacol Ther 64:622–635PubMedCrossRefGoogle Scholar
  7. 7.
    Hermida RC, Ayala DE, Fernández JR, Mojón A, Alonso I, Calvo C (2002) Modeling the circadian variability of ambulatorily monitored blood pressure by multiple-component analysis. Chronobiol Int 19:461–481PubMedCrossRefGoogle Scholar
  8. 8.
    Lee HW, Lim MS, Seong SJ et al (2011) Effect of age on the pharmacokinetics of fimasartan (BR-A-657). Expert Opin Drug Metab Toxicol 7(11):1337–1344PubMedCrossRefGoogle Scholar
  9. 9.
    Burnier M (2001) Angiotensin II Type 1 receptor blockers. Circulation 103:904–912PubMedCrossRefGoogle Scholar
  10. 10.
    Criscione L, Bradley WA, Bühlmayer P et al (1995) Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 13:230–250CrossRefGoogle Scholar
  11. 11.
    Mazzolai L, Maillard M, Rossat J, Nussberger J, Brunner HR, Burnier M (1999) Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists. Hypertension 33:850–855PubMedCrossRefGoogle Scholar
  12. 12.
    U.S Food and Drug Administration (2007) Diovan® (valsartan tablets) label. Accessed 22 Feb 2012
  13. 13.
    U.S Food and Drug Administration (2011) Cozaar® (losartan potassium tablets) label. Accessed 22 Feb 2012
  14. 14.
    U.S Food and Drug Administration (2011) ATCAND® (candesartan cilexetil tablets) label. Available at: Accessed 22 Feb 2012

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Jongtae Lee
    • 1
    • 2
  • Seunghoon Han
    • 1
    • 2
  • Sangil Jeon
    • 1
    • 2
  • Taegon Hong
    • 1
    • 2
  • Dong-Seok Yim
    • 1
    • 2
  1. 1.Department of Clinical Pharmacology and TherapeuticsSeoul St. Mary’s HospitalSeoulKorea
  2. 2.Department of Pharmacology, College of MedicineThe Catholic University of KoreaSeocho-gu, SeoulKorea

Personalised recommendations